74.92
price down icon0.25%   -0.19
after-market After Hours: 74.92
loading
Edwards Lifesciences Corp stock is traded at $74.92, with a volume of 2.34M. It is down -0.25% in the last 24 hours and up +8.02% over the past month. Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$75.11
Open:
$74.41
24h Volume:
2.34M
Relative Volume:
0.54
Market Cap:
$44.68B
Revenue:
$5.54B
Net Income/Loss:
$4.18B
P/E Ratio:
10.70
EPS:
7
Net Cash Flow:
$259.90M
1W Performance:
-1.78%
1M Performance:
+8.02%
6M Performance:
+13.95%
1Y Performance:
-11.95%
1-Day Range:
Value
$74.25
$75.36
1-Week Range:
Value
$74.15
$77.12
52-Week Range:
Value
$58.93
$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Name
Name
Edwards Lifesciences Corp
Name
Phone
(949) 250-2500
Name
Address
ONE EDWARDS WAY, IRVINE, CA
Name
Employee
15,800
Name
Twitter
@edwardslifesci
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
EW's Discussions on Twitter

Compare EW with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
EW
Edwards Lifesciences Corp
74.92 44.68B 5.54B 4.18B 259.90M 7.00
Medical Devices icon
ABT
Abbott Laboratories
133.06 227.05B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
104.12 152.00B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
377.52 139.34B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
82.32 108.50B 33.20B 4.26B 5.47B 3.29

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-24-25 Upgrade Piper Sandler Neutral → Overweight
Jan-30-25 Upgrade Stifel Hold → Buy
Jan-16-25 Downgrade Wolfe Research Peer Perform → Underperform
Dec-16-24 Upgrade BofA Securities Neutral → Buy
Oct-11-24 Resumed Morgan Stanley Equal-Weight
Sep-18-24 Downgrade Jefferies Buy → Hold
Jul-31-24 Upgrade Daiwa Securities Neutral → Outperform
Jul-29-24 Upgrade Wolfe Research Underperform → Peer Perform
Jul-25-24 Downgrade BofA Securities Buy → Neutral
Jul-25-24 Downgrade JP Morgan Overweight → Neutral
Jul-25-24 Downgrade Robert W. Baird Outperform → Neutral
Jul-25-24 Downgrade TD Cowen Buy → Hold
Jul-25-24 Downgrade Truist Buy → Hold
May-30-24 Initiated Goldman Buy
May-22-24 Upgrade Citigroup Neutral → Buy
May-14-24 Upgrade Deutsche Bank Hold → Buy
Mar-07-24 Upgrade BofA Securities Neutral → Buy
Feb-02-24 Upgrade Wells Fargo Equal Weight → Overweight
Jan-04-24 Downgrade Evercore ISI Outperform → In-line
Dec-11-23 Downgrade Citigroup Buy → Neutral
Nov-28-23 Downgrade Wolfe Research Peer Perform → Underperform
Sep-26-23 Upgrade Oppenheimer Perform → Outperform
Jul-19-23 Initiated Robert W. Baird Outperform
May-30-23 Resumed Morgan Stanley Overweight
Mar-29-23 Initiated UBS Neutral
Mar-08-23 Downgrade Wells Fargo Overweight → Equal Weight
Feb-06-23 Downgrade Raymond James Outperform → Mkt Perform
Jan-31-23 Downgrade Bernstein Outperform → Underperform
Jan-30-23 Downgrade Piper Sandler Overweight → Neutral
Dec-06-22 Downgrade Stifel Buy → Hold
Oct-28-22 Downgrade Oppenheimer Outperform → Perform
Oct-26-22 Initiated Mizuho Buy
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Buy
Jul-29-22 Downgrade Canaccord Genuity Buy → Hold
Apr-13-22 Initiated Truist Buy
Apr-06-22 Initiated Wolfe Research Outperform
Mar-16-22 Upgrade Bernstein Mkt Perform → Outperform
Mar-02-22 Resumed BofA Securities Neutral
Feb-02-22 Upgrade UBS Neutral → Buy
Jan-27-22 Reiterated Citigroup Buy
Jan-27-22 Reiterated Evercore ISI Outperform
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated Stifel Buy
Jan-27-22 Reiterated UBS Neutral
Dec-17-21 Upgrade JP Morgan Neutral → Overweight
Dec-15-21 Upgrade Citigroup Neutral → Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Dec-06-21 Upgrade Wells Fargo Equal Weight → Overweight
Jul-30-21 Reiterated Canaccord Genuity Buy
Jul-30-21 Reiterated Deutsche Bank Hold
Jul-30-21 Reiterated Jefferies Buy
Jul-30-21 Reiterated Morgan Stanley Overweight
Jul-30-21 Reiterated Oppenheimer Outperform
Jul-30-21 Reiterated Stifel Buy
Jul-30-21 Reiterated UBS Neutral
Jul-30-21 Reiterated Wells Fargo Equal Weight
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Apr-05-21 Upgrade Evercore ISI In-line → Outperform
Dec-16-20 Downgrade Citigroup Buy → Neutral
Dec-11-20 Reiterated Canaccord Genuity Buy
Sep-11-20 Initiated Wolfe Research Underperform
Apr-28-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-10-20 Initiated Oppenheimer Outperform
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Oct-24-19 Reiterated Canaccord Genuity Buy
Sep-23-19 Initiated Piper Jaffray Overweight
Jul-24-19 Reiterated BofA/Merrill Buy
Mar-18-19 Reiterated Canaccord Genuity Buy
Jan-18-19 Upgrade BofA/Merrill Neutral → Buy
Jan-03-19 Initiated Deutsche Bank Hold
Nov-28-18 Initiated UBS Neutral
Oct-16-18 Initiated Barclays Underweight
Oct-02-18 Downgrade BofA/Merrill Buy → Neutral
Oct-02-18 Downgrade Guggenheim Buy → Neutral
View All

Edwards Lifesciences Corp Stock (EW) Latest News

pulisher
07:05 AM

Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan

07:05 AM
pulisher
May 01, 2025

Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice

May 01, 2025
pulisher
May 01, 2025

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

FDA Approves First-Ever TAVR Treatment for Asymptomatic Aortic Stenosis Patients - Stock Titan

May 01, 2025
pulisher
Apr 30, 2025

Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey

Apr 30, 2025
pulisher
Apr 28, 2025

Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq

Apr 28, 2025
pulisher
Apr 26, 2025

Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 26, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, T - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, Target Raised | EW Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Piper Sandler raises Edwards Lifesciences stock to Overweight - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast By Investing.com - Investing.com UK

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Milestones - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Reports Strong Q1 2025 Growth on Cardi - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Reports Strong Q1 Growth - TipRanks

Apr 24, 2025
pulisher
Apr 23, 2025

Edwards posts Street-beating Q1 results, ups 2025 sales guidance - MassDevice

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Corp Q1 2025 Earnings: EPS of $0.62 Beats E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences raises 2025 sales forecast after robust quarter - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Innovative Strategy Boosts Edwards Lifesciences (EW) Q1 Revenue Above Expectations | EW Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Reports First Quarter Results - TradingView

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Corp. Reveals Climb In Q1 Profit - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Earnings Flash (EW) Edwards Lifesciences Reports Q1 Adjusted EPS $0.64, vs. FactSet Est of $0.60 - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Crushes Q1 Expectations: TMTT Sales Surge 58%, New SAPIEN M3 Approval Fuels Growth - Stock Titan

Apr 23, 2025
pulisher
Apr 21, 2025

EDWARDS LIFESCIENCES Earnings Preview: Recent $EW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue - BioSpace

Apr 21, 2025
pulisher
Apr 19, 2025

Lobbying Update: $350,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 18, 2025

Edwards touts 8-year data for Resilia valve tissue - MassDevice

Apr 18, 2025
pulisher
Apr 18, 2025

Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan

Apr 18, 2025
pulisher
Apr 17, 2025

Is Edwards Lifesciences Gaining or Losing Market Support?Edwards Lifesciences (NYSE:EW) - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com

Apr 16, 2025

Edwards Lifesciences Corp Stock (EW) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$81.53
price up icon 1.57%
$67.09
price down icon 3.29%
medical_devices STE
$222.45
price down icon 0.82%
medical_devices PHG
$24.09
price down icon 6.05%
medical_devices ZBH
$92.27
price up icon 1.98%
Cap:     |  Volume (24h):